Subtotal $0.00
Shop Now
GLP-1 Alzheimer’s research reached a clear answer in 2025 and 2026: in two large phase 3 trials, semaglutide did not slow Alzheimer’s disease. The EVOKE and EVOKE+ trials randomized 3,808 people aged 55 to 85 with early, amyloid-confirmed Alzheimer’s to daily oral semaglutide or placebo. After two years, decline on the main memory-and-function scale was the same in both groups, and the results were published in The Lancet in March 2026. The idea came from observational studies in people with type 2 diabetes, where GLP-1 users had fewer dementia diagnoses, but those studies cannot prove cause and effect. No GLP-1 medicine is approved for Alzheimer’s or dementia. Anyone worried about memory should see a doctor or neurologist.
Peptide Labs does not sell Ozempic, Wegovy, Rybelsus or any prescription drug. This article summarizes published trials and FDA labels. For background on how these medicines work, see what GLP-1 is.
Key Takeaways
- The EVOKE and EVOKE+ trials found that oral semaglutide did not slow early Alzheimer's disease.
- Some blood and spinal fluid markers changed, but memory and daily function did not improve.
- Earlier hopes came from animal studies and observational data in people with type 2 diabetes.
- Observational studies show associations, not proof; confounding and diagnosis patterns can mislead.
- A smaller liraglutide trial (ELAD) also missed its main goal.
- No GLP-1 medicine is approved to prevent or slow Alzheimer's disease or other dementias.
Why researchers tested GLP-1 Alzheimer's ideas
GLP-1 receptors are found in the brain as well as the gut and pancreas. Animal studies suggested GLP-1 drugs might reduce inflammation and protect nerve cells, and people with type 2 diabetes have a higher risk of dementia. Novo Nordisk said its decision to test semaglutide in Alzheimer’s was based on real-world evidence studies, preclinical models and post-hoc analyses of earlier trials.
The observational signals
- 2022 pooled analysis: in three placebo-controlled heart outcome trials of GLP-1 drugs in 15,820 people with type 2 diabetes, dementia was diagnosed less often in the drug groups (hazard ratio 0.47). A Danish registry of 120,054 patients showed a smaller association. Three authors were Novo Nordisk employees, and dementia was not a planned outcome of those trials.
- 2024 health-record study: among about 1.1 million U.S. patients with type 2 diabetes, semaglutide users had fewer first-time Alzheimer’s diagnoses over three years than users of seven other diabetes drugs. The authors declared no competing interests and called for randomized trials.
Studies like these compare people who received different drugs in everyday care. Even with careful matching, the groups can differ in health, income, weight, doctor visits and how often memory problems are noticed and recorded. Reverse causation is another trap: people already in the earliest, unnoticed stage of memory decline may be less likely to be started on a newer medicine, which would make the newer drug look protective. Observational results are a reason to run a trial, not an answer in themselves. That is why a randomized trial was needed.
Semaglutide Alzheimer's results: the EVOKE trial
The EVOKE trial and its sister trial EVOKE+ were the definitive test of semaglutide Alzheimer’s effects. Both were double-blind and placebo-controlled, ran at 566 sites in 40 countries and were funded by Novo Nordisk. EVOKE+ also allowed people with significant small-vessel disease in the brain.
| Feature | EVOKE | EVOKE+ |
|---|---|---|
| People randomized | 1,855 | 1,953 |
| Who | Ages 55 to 85, mild cognitive impairment or mild dementia, amyloid-confirmed | Same, plus some with small-vessel disease |
| Medicine | Once-daily oral semaglutide vs placebo | Once-daily oral semaglutide vs placebo |
| Main measure | Change in CDR-SB score at week 104 | Change in CDR-SB score at week 104 |
| Result | 2.3 vs 2.3 points of decline; no difference | 2.2 vs 2.1 points of decline; no difference |
The CDR-SB (Clinical Dementia Rating, Sum of Boxes) scores memory, orientation, judgment, community affairs, home life and personal care; higher scores mean more impairment. Secondary measures of thinking and daily activities also showed no meaningful differences, according to the December 2025 conference presentation. Semaglutide improved some Alzheimer’s-related biomarkers, but in the company’s words this did not translate into a delay of disease progression. The planned one-year extension was stopped.
Side effects matched what is known for semaglutide: adverse events were reported by 91.2% on semaglutide and 84.8% on placebo, mostly digestive symptoms and weight loss, and no new safety concerns appeared. The authors concluded that oral semaglutide was not efficacious in slowing clinical progression in early Alzheimer’s disease.
Other GLP-1 dementia trials
The ELAD trial, published in Nature Medicine, gave daily liraglutide or placebo for 52 weeks to 204 people with mild to moderate Alzheimer’s who did not have diabetes. Its main goal, a change in brain glucose use on PET scans, showed no significant difference, and there was no difference on the CDR-SB or a daily-activities scale. One executive-function score favored liraglutide, but it was a secondary result without adjustment for multiple comparisons.
Some researchers argue that GLP-1 drugs might still matter earlier, before symptoms, or by lowering risk factors such as diabetes, obesity and high blood pressure over many years. That is a hypothesis, not a finding; EVOKE tested people who already had symptoms, and prevention trials would take years.
Does Ozempic cause or stop dementia?
People searching for Ozempic dementia information usually want to know one of two things. On prevention, there is no randomized evidence that semaglutide lowers the risk of dementia, and the large trials in people who already had early Alzheimer’s were negative. On harm, the Ozempic label (revised May 2026) does not list dementia or memory loss among its side effects. Confusion and drowsiness do appear in the Medication Guides as possible signs of low blood sugar, a risk mainly when these medicines are combined with insulin or a sulfonylurea. Full lists are in our guides to semaglutide side effects and GLP-1 side effects.
What this means if you or a relative has memory problems
- Memory changes deserve a medical assessment; some causes, such as thyroid problems, vitamin B12 deficiency, depression, sleep problems and medicine side effects, can be addressed.
- A neurologist or memory clinic can discuss approved Alzheimer’s medicines and clinical trials that may be recruiting.
- Do not start or continue a GLP-1 medicine to protect memory; there is no approved use or proven benefit.
- If you already take a GLP-1 medicine for diabetes or weight, the trial result is not a reason to stop it without talking to your prescriber. Its approved benefits are covered in our summary of GLP-1 trial results.
Sudden confusion, trouble speaking, weakness on one side or a severe headache can signal a stroke or another emergency. Call 911 right away.
Frequently Asked Questions
Does semaglutide help Alzheimer’s disease?
No. In the EVOKE and EVOKE+ trials of 3,808 people with early Alzheimer’s, oral semaglutide did not slow decline in memory or daily function compared with placebo over two years.
What was the EVOKE trial?
EVOKE and EVOKE+ were Novo Nordisk-funded phase 3 trials testing daily oral semaglutide against placebo in people aged 55 to 85 with mild cognitive impairment or mild dementia due to Alzheimer’s.
Why did people think GLP-1 drugs might help with Alzheimer’s?
Animal studies and observational data in people with type 2 diabetes linked GLP-1 drugs with fewer dementia diagnoses. Those studies show associations and cannot prove the drug caused the difference.
Does Ozempic cause dementia?
Dementia is not listed as a side effect on the Ozempic label. Confusion can be a sign of low blood sugar, mainly when it is combined with insulin or a sulfonylurea.
Can GLP-1 drugs prevent dementia?
That has not been shown in randomized trials. Some researchers think long-term control of diabetes, weight and blood pressure could matter, but this remains a hypothesis.
Is any GLP-1 medicine approved for Alzheimer’s?
No. No GLP-1 medicine is approved for Alzheimer’s disease or any other dementia. A neurologist can explain the approved options.
Peptide Labs does not sell GLP-1 medicines or any prescription drug. This article is general information, not medical advice. Read the Medication Guide that comes with a prescription, and ask a pharmacist or prescriber how this information applies to you.
Last reviewed October 2026.
Related guides: What Is GLP-1? The Hormone, How GLP-1 Drugs Work and Every FDA-Approved Option, Semaglutide Side Effects: What the Ozempic, Wegovy and Rybelsus Labels Say, GLP-1 for Weight Loss: What the Trials Actually Showed.